PharmExec
JANUARY 8, 2024
Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.
Fierce Pharma
JANUARY 9, 2024
Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. | Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Morgan Healthcare Conference on Monday, the company’s CEO, Albert Bourla, spoke bluntly about the hits the company took, and he acknowledged the underperformance of certain key launches.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JANUARY 10, 2024
In 2023, digital health fundraising took on a bit of a different shape, according to a new Rock Health report. Startups tried out some creative ways to keep their businesses afloat — including series extension rounds, unlabeled fundraises and silent deals from existing investors.
European Pharmaceutical Review
JANUARY 9, 2024
Revolutionising quality control In the backdrop of stringent quality standards and regulatory demands inherent to pharmaceutical manufacturing, the addition of AI technologies introduce a paradigm shift. This article highlights the manifold applications of AI, particularly cutting-edge image recognition and computer vision systems, which profoundly impact quality control.
PharmaVoice
JANUARY 11, 2024
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
Fierce Pharma
JANUARY 8, 2024
San Francisco—Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. | Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. On Monday, the Swiss pharma’s CEO Vas Narasimhan explained how he's resisted the temptation.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
JANUARY 11, 2024
The European Commission (EC) has granted a marketing authorisation for Uzpruvo ® (AVT04) in Europe, a biosimilar candidate to Stelara ® (ustekinumab). Ustekinumab biologic Once the European Supplementary Protection Certificate (SPC) for Stelara expires in July 2024, this will open up market entry as soon as possible for Uzpruvo, now that it is approved in Europe” Ustekinumab is a human IgG1κ monoclonal antibody (mAb).
PharmExec
JANUARY 9, 2024
Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.
Fierce Pharma
JANUARY 8, 2024
While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” | While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.
MedCity News
JANUARY 7, 2024
Protecting rural healthcare and pharmaceutical networks is an ongoing effort that requires comprehensive cybersecurity that goes beyond traditional IT systems, combining technical solutions, employee education, and a commitment to staying up to date with evolving cyber threats.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
JANUARY 11, 2024
Quotient Sciences leverage more than 30 years of drug development expertise to support small molecule and synthetic peptide drug programmes, in both simple drug programmes as well as complex cases where specialised formulation expertise and technologies are required. All drug development programmes are challenging, with numerous stages that an active, lead molecule or new chemical entity (NCE) must transition through to gain regulatory approval and demonstrate its benefits to patients Find out m
pharmaphorum
JANUARY 10, 2024
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour subcutaneous infusion therapy for the neurodegenerative disorder.
Fierce Pharma
JANUARY 8, 2024
Johnson & Johnson is starting the year with a new corporate identi | Despite all the recent changes at Johnson & Johnson, the company maintains an aggressive outlook for its pharmaceuticals division. In fact, J&J's sales forecasts for some drugs come in vastly higher than analyst numbers.
MedCity News
JANUARY 8, 2024
Through a new partnership, payers and providers will be able to leverage Socially Determined’s social risk data to identify which patients have barriers to accessing healthcare and what those barriers are. Uber Health will then be able to offer its services to support those patients’ specific needs, whether it’s non-emergency medical transportation, same-day prescription delivery or grocery and over-the-counter item delivery.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
JANUARY 12, 2024
Using an investment of €120 million, Boehringer Ingelheim is set to expand and upgrade its production site in Koropi, Greece. New technologies at the facility will support the increased manufacturing capacity, the company stated on X. The expansion will boost exports of medicines from Greece to the US market. This will be the case particularly for Jardiance ® , a treatment for type 2 diabetes, chronic heart failure and chronic kidney disease (CKD), according to Boehringer Ingelheim.
pharmaphorum
JANUARY 9, 2024
Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug candidates for cancer.
Fierce Pharma
JANUARY 11, 2024
Dermavant’s topical cream Vtama, already on the market for plaque psoriasis as a steroid-free treatment, is compiling impressive data in pursuit of an FDA approval in atopic dermatitis (AD). | Dermavant’s topical cream Vtama, already on the market for plaque psoriasis as a steroid-free treatment, is compiling impressive data in pursuit of an FDA approval in atopic dermatitis (AD).
MedCity News
JANUARY 8, 2024
It’s high time we reframe how we think about lung cancer by ending the shame and judgment. I care less about if you quit smoking, I care more that you get screened. No one should have to die, period.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Commerce
JANUARY 12, 2024
An overview of a structural approach that guides development of the analytics and related reporting that may assist brands in gaining or maintaining reimbursement positions and maximizing sales.
pharmaphorum
JANUARY 10, 2024
Precision BioSciences licenses non-cancer uses of its allogeneic CAR-T therapy azer-cel to TG Therapeutics as it pivots to in vivo applications of its gene-editing technology
Fierce Pharma
JANUARY 8, 2024
It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday
MedCity News
JANUARY 9, 2024
XRHealth’s $6 million in funding was led by Asabys Partners and included participation from NOVA Prime Fund. The company will use the funding to support its recent merger with Amelia Virtual Care.
PharmExec
JANUARY 8, 2024
In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.
pharmaphorum
JANUARY 8, 2024
Servier has added a third digital twin project to its collaboration with AI specialist Aitia, trying to identify Parkinson's patients who will respond to its LRRK2 inhibitor in clinical trials.
Fierce Pharma
JANUARY 10, 2024
With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. Morgan Healthcare Conference. Besides that goal, the company wants to be a top-3 player in its five disease areas of focus.
MedCity News
JANUARY 11, 2024
At CES 2024, menopause startup Amira launched The Terra System, a wearable cooling device that supports women battling hot flashes and helps them sleep through the night.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
JANUARY 11, 2024
chronic neuropathic pain is at present, mainly managed with antidepressants… antiepileptic drugs… as well as opioids” Neuropathic pain affects over 400 million people worldwide, according to Hoba Therapeutics. In Europe, the prevalence of chronic neuropathic pain is estimated to be six–eight percent 1 of the general population. Drug development for pain management is “incredibly complex… mainly because the trials are so challenging to conduct”, the company highlight
pharmaphorum
JANUARY 8, 2024
Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships
Fierce Pharma
JANUARY 8, 2024
Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said.
MedCity News
JANUARY 9, 2024
Walgreens has agreed to pay Humana $360 million to settle a drug pricing dispute that has spanned nearly five years. The payout is roughly half of what Walgreens was originally ordered to pay when the issue was first resolved last year.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
126 
Let's personalize your content